🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInsurance & AccessCompounded GLP-1 cost breakdown — looking for input

Compounded GLP-1 cost breakdown — looking for input

Dr.AddMedPHL Thu, Mar 5, 2026 at 7:18 PM 7 replies 825 viewsPage 1 of 2
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Mar 5, 2026 at 7:18 PM#1

Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within weeks of each other.

What I actually want to know is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material.

Numbers rather than impressions, if you have them.

21 16FitDadDave, RunnerRach, TrialNerd_Beth and 18 others
Reply Quote Save Share Report
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Mar 5, 2026 at 7:30 PM#2

Taking the question as asked, rather than the general version of it. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

Last edited: Mar 5, 2026 at 10:30 PM
20 15laura_annarbor, JenMemphis, pat_auckland and 17 others
Reply Quote Save Share Report
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Mar 5, 2026 at 7:42 PM#3
LabKate said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

LabKate has the substance of this right. The condition it depends on is worth stating. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

19 14WendyG_ATL, SaraMom3, Dr.MetabolicMD and 16 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
tommy_boulder
Member
234
1,123
Nov 2024
Boulder, CO
Mar 5, 2026 at 7:54 PM#4
Dr.AddMedPHL said:
Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within…

Can confirm the pattern Dr.AddMedPHL describes. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

That is the short version; the long version is somebody else's post.

18 13dan_philly, MeganSA_TX, LarryQC_SD and 15 others
Reply Quote Save Share Report
JenPlateau
Member
234
890
Nov 2024
Missouri
Mar 5, 2026 at 8:59 PM#5

From the other side of the consultation, briefly.

Compounding pharmacy response time test for compounded supply: I email customer service at odd hours to test responsiveness. A pharmacy that can't answer questions promptly is a red flag.

My current pharmacy: average response time same day. They answered my questions about sterility testing thoroughly and professionally.

Communication quality is a proxy for operational quality. A pharmacy that communicates well is likely manufacturing well too.

17 12sarah_nash92, FitDadDave, RunnerRach and 14 others
Reply Quote Save Share Report

Similar Threads

Prior authorization success: step-by-step guide with templates5 replies
Cigna now covering Zepbound — how I got approved13 replies
Appeal letter template — denied PA for GLP-1 medications4 replies
Mounjaro savings card — manufacturer program changes 202610 replies
Medicare Part D GLP-1 coverage — what's covered in 202610 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register